Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer

This study has been terminated.
(Early closure based on audit by study investigators after 3 patients died on study.)
Brigham and Women's Hospital
Massachusetts General Hospital
Information provided by (Responsible Party):
Ursula A. Matulonis, MD, Dana-Farber Cancer Institute Identifier:
First received: May 5, 2006
Last updated: June 12, 2015
Last verified: June 2015

The main purpose of this trial is to look at how elderly women (70 years of age or older) with newly diagnosed ovarian, peritoneal, or fallopian tube cancer manage six cycles of carboplatin and paclitaxel, what side effects they experience, and how their cancer reacts or responds to standard carboplatin and paclitaxel chemotherapy.

Condition Intervention Phase
Ovarian Cancer
Primary Peritoneal Carcinoma
Fallopian Tube Cancer
Mixed Tumor, Mesodermal
Drug: Paclitaxel
Drug: Carboplatin
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer

Resource links provided by NLM:

Further study details as provided by Dana-Farber Cancer Institute:

Primary Outcome Measures:
  • Therapy Completion Rate [ Time Frame: 6 cycles of therapy, up to approximately 4.5 months given the cycle length of 21 days. ] [ Designated as safety issue: Yes ]
    The therapy completion rate is the proportion of patients who completed 6 cycles of carboplatin/paclitaxel therapy without dose reductions.

Enrollment: 12
Study Start Date: April 2006
Study Completion Date: April 2010
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Carboplatin/Paclitaxel
Patients received chemotherapy on day 1 of a 21 day cycle for 6 cycles. Paclitaxel was given via peripheral or central IV catheter at the dose of 175 mg/m2 over 3 hours. IV carboplatin followed using a dose of Area Under the Curve (AUC) equal to 5 with creatinine clearance based on Jelliffe formula.
Drug: Paclitaxel
Other Name: Taxol
Drug: Carboplatin

Detailed Description:



•To determine the completion rate of six cycles of carboplatin/paclitaxel with no dose reductions because of toxicities.


  • Assess cancer antigen 125 (CA125) response rates of paclitaxel/carboplatin in this group of patients
  • Assess significant toxicities in this group of patients and compare to a non-elderly population.
  • To determine which clinical parameters will predict lack of completion of six cycles of carboplatin and paclitaxel chemotherapy.
  • Assess quality of life changes during chemotherapy and up to one year after completion of chemotherapy.
  • Assess progression-free survival and overall survival for this group.
  • To determine the feasibility of accrual.


Using a one sample binomial design, with 37 patients there was 83% power to detect a null hypothesis of a 45% therapy completion rate versus an alternative hypothesis of a 66% rate assuming a one-sided 5% alpha. The regimen would be declared ineffective if there were 19 or fewer patients who completed 6 cycles of carboplatin and paclitaxel chemotherapy without dose adjustments.


Ages Eligible for Study:   70 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 70 or older
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2 and is medically eligible and clinically appropriate to receive systemic chemotherapy
  • Diagnosis of ovarian, primary peritoneal, fallopian tube cancer, papillary serous cancer of the endometrium, or mixed mesodermal tumors of the ovary, fallopian tube or uterus
  • Life expectancy greater than 6 months
  • Baseline laboratory values as described in protocol

Exclusion Criteria:

  • Active infection requiring antibiotics at the time of starting chemotherapy
  • Prior pelvic radiotherapy > 25% of bone marrow
  • Any uncontrolled medical problem that in the opinion of the investigator would preclude safe administration of the study drugs
  • Past history of bone marrow transplantation or stem cell support
  • Known history of central nervous system (CNS) metastasis
  • History of prior malignancy that required prior systemic therapy
  • Clinically significant cardiac disease
  • Uncontrolled diabetes mellitus
  • Any signs of intestinal obstruction
  • Participation in an investigational drug study within three weeks prior to study entry
  • History of psychiatric disability or other central nervous system disorder
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00322881

United States, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02155
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Massachusetts General Hospital
Principal Investigator: Ursula Matulonis, MD Dana-Farber Cancer Institute
  More Information

Responsible Party: Ursula A. Matulonis, MD, Medical Oncologist, Dana-Farber Cancer Institute Identifier: NCT00322881     History of Changes
Other Study ID Numbers: 05-402
Study First Received: May 5, 2006
Results First Received: January 6, 2015
Last Updated: June 12, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by Dana-Farber Cancer Institute:
elderly women

Additional relevant MeSH terms:
Mixed Tumor, Mesodermal
Neoplasms by Histologic Type
Neoplasms, Complex and Mixed
Neoplasms, Connective and Soft Tissue
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators processed this record on October 13, 2015